Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients

Journal of Experimental & Clinical Cancer Research

Alessandro Sgambato¹  Achille Cittadini¹  Egidio Stigliano²  Giannicola Genovese¹  Luca Reggiani Bonetti⁴  Gianluca Rizzo³  Mario Migaldi⁴  Alma Boninsegna¹  Stefano Sioletic¹  Emanuele Caredda¹  Gian Franco Zannoni²  Claudio Coco³ 

[1] Istituto di Patologia Generale, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, Rome 00168, Italy;Istituto di Anatomia Patologica, Università Cattolica del Sacro Cuore, Rome, Italy;Dipartimento di Scienze Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy;Dipartimento Misto di Anatomia Patologica e di Medicina Legale, Sezione di Anatomia Patologica, University of Modena and Reggio Emilia, Modena, Italy

关键词: Survival analysis;    Prognostic marker;    Cancer stem cell;    CD133;    Dystroglycan;    Colon cancer;   

Others  :  826035
DOI  :  10.1186/1756-9966-31-71

 received in 2012-08-01, accepted in 2012-08-28,  发布年份 2012

【 摘 要 】

Background

Expression levels of CD133, a cancer stem cell marker, and of the α-subunit of the dystroglycan (α-DG) complex, have been previously reported to be altered in colorectal cancers.

Methods

Expression levels of CD133 and α-DG were assessed by immunohistochemistry in a series of colon cancers and their prognostic significance was evaluated.

Results

Scattered cells positive for CD133 were rarely detected at the bases of the crypts in normal colonic mucosa while in cancer cells the median percentage of positive cells was 5% (range 0–80). A significant correlation was observed with pT parameter and tumor stage but not with tumor grade and N status. Recurrence and death from disease were significantly more frequent in CD133-high expressing tumors and Kaplan-Meier curves showed a significant separation between high vs low expressor groups for both disease-free (p = 0.002) and overall (p = 0.008) survival.

Expression of α-DG was reduced in a significant fraction of tumors but low α-DG staining did not correlate with any of the classical clinical-pathological parameters. Recurrence and death from the disease were significantly more frequent in α-DG-low expressing tumors and Kaplan-Meier curves showed a significant separation between high vs low expressor tumors for both disease-free (p = 0.02) and overall (p = 0.02) survival. Increased expression of CD133, but not loss of α-DG, confirmed to be an independent prognostic parameters at a multivariate analysis associated with an increased risk of recurrence (RR = 2.4; p = 0.002) and death (RR = 2.3; p = 0.003).

Conclusions

Loss of α-DG and increased CD133 expression are frequent events in human colon cancer and evaluation of CD133 expression could help to identify high-risk colon cancer patients.

【 授权许可】

   
2012 Coco et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Horst D, Kriegl L, Engel J, Kirchner T, Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008, 99:1285-1289.
• [2]Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008, 99:1578-1583.
• [3]Li C, Li B, Liang Y, Peng R, Ding Y, Xu D, et al.: Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009, 7:56. BioMed Central Full Text
• [4]Winder SJ: The complexities of dystroglycan. TIBS 2001, 26:118-124.
• [5]Muschler J, Levy D, Boudreau R, Henry M, Campbell K, Bissell MJ: A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells. Cancer Res 2002, 62:7102-7109.
• [6]Sgambato A, Brancaccio A: The dystroglycan complex: from biology to cancer. J Cell Physiol 2005, 205:163-169.
• [7]Sgambato A, Di Salvatore M, De Paola B, Rettino A, Faraglia B, Boninsegna A, et al.: Analysis of dystroglycan regulation and functions in mouse mammary epithelial cells and implications for mammary tumorigenesis. J Cell Physiol 2006, 207:520-529.
• [8]Calogero A, Pavoni E, Gramaglia T, D'Amati G, Ragona G, Brancaccio A, et al.: Altered exression of a-dystroglycan subunit in human gliomas. Cancer Biol Ther 2006, 5:441-448.
• [9]Sgambato A, Camerini A, Montanari M, Camerini A, Brancaccio A, Spada D, et al.: Increased expression of dystroglycan inhibits the growth and tumorigenicity of human mammary epithelial cells. Cancer Biol Ther 2004, 3:849-860.
• [10]Sgambato A, De Paola B, Migaldi M, Di Salvatore M, Rettino A, Rossi G, et al.: Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 2007, 213:528-539.
• [11]Compton C, Greene F: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004, 54:295-308.
• [12]Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, et al.: Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 2003, 162:849-860.
• [13]Zannoni G, Faraglia B, Tarquini E, Camerini A, Vrijens K, Migaldi M, et al.: Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions. Mod Pathol 2006, 19:504-513.
• [14]Sgambato A, Tarquini E, Resci F, De Paola B, Faraglia B, Camerini A, et al.: Aberrant expression of alpha-dystroglycan in cervical and vulvar cancer. Gynecol Oncol 2006, 103:397-404.
• [15]Jiang X, Rieder S, Giese N, Friess H, Michalski C, Kleeff J: Reduced alpha-dystroglycan expression correlates with shortened patient survival in pancreatic cancer. J Surg Res 2011, 171:120-126.
• [16]Shen JG, Xu CY, Li X, Dong M, Jiang ZN, Wang J, et al.: Dystroglycan is associated with tumor progression and patient survival in gastric cancer. Pathol Oncol Res 2012, 18:79-84.
• [17]Bao X, Fukuda M: A tumor suppressor function of laminin-binding alpha-dystroglycan. Methods Enzymol 2010, 479:387-396.
• [18]Brennan P, Jing J, Ethunandan M, Gorecki D: Dystroglycan complex in cancer. Eur J Surg Oncol 2004, 30:589-592.
• [19]Henry MD, Cohen MB, Campbell KP: Reduced expression of dystroglycan in breast and prostate cancer. Hum Pathol 2001, 32:791-795.
• [20]Cross S, Lippitt J, Mitchell A, Hollingsbury F, Balasubramanian S, Reed M, et al.: Expression of beta-dystroglycan is reduced or absent in many human carcinomas. Histopathology 2008, 53:561-566.
• [21]Losasso C, Di Tommaso F, Sgambato A, Ardito R, Cittadini A, Giardina B, et al.: Anomalous dystroglycan in carcinoma cell lines. FEBS Lett 2000, 484:194-198.
• [22]Herzog C, Has C, Franzke C-W, Echtermeyer F, Schlotzer-Schrehardt U, Kroger S, et al.: Dystroglycan in skin and cutaneous cells: ß-subunit is shed from the cell surface. J Invest Dermatol 2004, 122:1372-1380.
• [23]Jing J, Lien CF, Sharma S, Rice J, Brennan PA, Gorecki DC: Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas. European J Cancer 2004, 40:2143-2151.
• [24]Singh J, Itahana Y, Knight-Krajewski S, Kanagawa M, Campbell KP, Bissell MJ, et al.: Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. Cancer Res 2004, 64:6152-6159.
• [25]de Bernabé D, Inamori K, Yoshida-Moriguchi T, Weydert C, Harper H, Willer T, et al.: Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE. J Biol Chem 2009, 284:11279-11284.
• [26]Holt KH, Crosbie RH, Venzke DP, Campbell KP: Biosynthesis of dystroglycan: processing of a precursor peptide. FEBS Lett 2000, 468:79-83.
• [27]O’Brien C, Pollett A, Gallinger S, Dick J: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
• [28]Ricci-Vitiani L, Lombardi D, Signore M, Biffoni M, Pallini R, Parati E, et al.: Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
• [29]Shmelkov S, Butler J, Hooper A, Hormigo A, Kushner J, Milde T, et al.: CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118:2111-2120.
• [30]Horst D, Kriegl L, Engel J, Kirchner T: A J. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009, 27:844-850.
• [31]Horst D, Scheel S, Liebmann S, Neumann J, Maatz S, Kirchner T, et al.: The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009, 219:427-434.
• [32]Puglisi M, Barba M, Corbi M, Errico M, Giorda E, Saulnier N, et al.: Identification of Endothelin-1 and NR4A2 as CD133-regulated genes in colon cancer cells. J Pathol 2011, 225:305-314.
• [33]Sgambato A, Puglisi M, Errico F, Rafanelli F, Boninsegna A, Rettino A, et al.: Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. J Cell Physiol 2010, 224:234-241.
• [34]Sgambato A, Errico F, Caredda E, Puglisi M, Cittadini A: Divergent expression of CD133 in different studies: the need for a consensus panel? Int J Cancer 2010, 128:2247-2249.
• [35]Hermansen S, Christensen K, Jensen S, Kristensen B: Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 2011, 59:391-407.
• [36]Mak A, Blakely K, Williams R, Penttila P, Shukalyuk A, Osman K, et al.: CD133 N-glycosylation processing contributes to cell-surface recognition of the primitive cell marker AC133. J Biol Chem 2011, 31:4273-4275.
• [37]Xi H, Zhao P: Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 2011, 64:498-503.
• [38]Arena V, Caredda V, Cufino V, Stigliano E, Scaldaferri F, Gasbarrini A, et al.: Differential CD133 expression pattern during mouse colon tumorigenesis. Anticancer Res 2011, 31:4273-4275.
• [39]Hibi K, Sakata M, Sakuraba K, Shirahata A, Goto T, Mizukami H, et al.: CD133 gene overexpression is frequently observed in early colo-rectal carcinoma. Hepatogastroenterology 2009, 56:995-997.
• [40]Keysar S, Jimeno A: More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 2010, 9:2450-2457.
• [41]Huang X, Sheng Y, Guan M: Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis. Surg Oncol 2012, 21:103-107.
• [42]Puglisi M, Sgambato A, Saulnier N, Rafanelli F, Barba M, Boninsegna A, et al.: Isolation and characterization of CD133+ population within human primary and metastatic colon cancer. Eur Rev Med Pharmacol Sci 2009, 13(Suppl 1):55-62.
• [43]Deng W, Schneider M, Frock R, Castillejo-Lopez C, Gaman E, Baumgartner S, et al.: Dystroglycan is required for polarizing the epithelial cells and the oocyte in Drosophila. Development 2003, 130:173-184.
• [44]Feng H, Liu Y, Yang L, Bian X, Yang Z, Gu B, et al.: Expression of CD133 correlates with differentiation of human colon cancer cells. Cancer Biol Ther 2010, 9:215-222.
• [45]Kemper K, Sprick M, de Bree M, Scopelliti A, Vermeulen L, Hoek M, et al.: The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010, 70:719-729.
• [46]Yang K, Chen X, Zhang B, Yang C, Chen H, Chen Z, et al.: Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 2011, 26:173-180.